Who Supplies Doxycycline to India from UNITED KINGDOM

To import finished pharmaceutical formulations containing Doxycycline into India, obtaining an Import Registration and License from the Central Drugs Standard Control Organization (CDSCO) is mandatory. This requirement is stipulated under the Drugs and Cosmetics Act, 1940, and its associated rules. The CDSCO evaluates the safety, efficacy, and quality of the product before granting approval. The registration process involves submitting comprehensive documentation, including product details, manufacturing information, and compliance with Indian Pharmacopoeia standards. The timeline for obtaining CDSCO approval can vary, but it typically ranges from several months to over a year, depending on the complexity of the product and the completeness of the application.

Imported pharmaceutical formulations containing Doxycycline must undergo quality testing at CDSCO-approved laboratories in India. This includes batch-wise testing to ensure compliance with Indian Pharmacopoeia standards. A Certificate of Analysis (CoA) is required for each batch, along with stability data demonstrating the product's shelf-life under Indian climatic conditions (ICH Zone IV). Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays and financial losses for the importer.

In April 2025, the CDSCO introduced new regulations mandating import registration and licenses for all pharmaceutical imports, including finished formulations containing Doxycycline. This move aims to prevent the sale of unapproved or illegal medicines in the Indian market. The regulations also specify procedures for transferring drugs manufactured in Special Economic Zones (SEZs) to the Domestic Tariff Area (DTA) for sale and distribution, ensuring that these drugs meet quality, safety, and efficacy standards.

India imports finished Doxycycline formulations to meet the demand for specific dosage forms and branded products not manufactured domestically. The domestic pharmaceutical industry may lack the capacity to produce certain formulations, leading to reliance on imports. The market size for Doxycycline formulations in India is substantial, with a total export market of $118.6 million across 408 exporters to 149 countries. This indicates a significant demand for Doxycycline products within the country.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10%, and an Integrated Goods and Services Tax (IGST) of 12%. The total landed duty amounts to approximately 23.536% of the Cost, Insurance, and Freight (CIF) value. This structure is designed to regulate the import of pharmaceutical products and protect domestic manufacturers.

India sources finished Doxycycline formulations from the United Kingdom due to the availability of patented and specialized dosage forms that may not be produced domestically. The United Kingdom's pharmaceutical industry is known for its high-quality standards and compliance with international regulations, making it a reliable source for such imports. Other suppliers, such as China, Germany, and the United States, also export Doxycycline formulations to India, but the United Kingdom's competitive advantage lies in its established trade relations and consistent product quality.

India imports finished Doxycycline formulations from the United Kingdom to access patented formulations and specialized dosage forms not available domestically. The United Kingdom's pharmaceutical industry offers high-quality products that meet international standards, ensuring efficacy and safety. These imported formulations fulfill specific market needs and patient requirements, contributing to the diversity and availability of Doxycycline products in India.

When compared to other sources like China, Germany, and the United States, the United Kingdom offers a competitive advantage in terms of product quality, regulatory compliance, and established trade relations with India. While other countries may offer lower prices, the United Kingdom's consistent product quality and adherence to international standards make it a preferred choice for importing finished Doxycycline formulations.

Indian importers face several risks when sourcing finished Doxycycline formulations from the United Kingdom, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, ensure robust quality assurance processes, and maintain contingency plans for shipping disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to assess supplier reliability and compliance with quality standards.
5. 5Regulatory Compliance: Ensure all imports comply with CDSCO regulations and obtain necessary licenses and registrations.

Implementing these strategies will enhance the resilience and efficiency of the procurement process for finished Doxycycline formulations.